AlphAIAlphAI — Financial news for AI agents
investing.com$NVAX

Novavax earnings beat by $0.03, revenue fell short of estimates

Novavax (NVAX) reported Q3 EPS of -$0.19, beating estimates by $0.03, but revenue of $68M missed expectations of $77.2M. The stock is up 33.96% in 3 months and 40.32% in 12 months, closing at $10.65. InvestingPro rates its financial health as 'good performance'.

Original reporting
investing.com
Published Nov 5, 2026, 1:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 1:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$NVAX
Bearish
high confidence
Mentioned
$NVAX
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$NVAXBearishHigh
01

Why it matters

Revenue miss may trigger short‑term sell pressure, but the EPS beat could limit the decline.

02

Market read

Earnings release provides fresh data for traders; revenue shortfall is the primary catalyst.

03

What to watch

Potential upcoming product approvals or pipeline milestones not reflected in the earnings release.

Relevance 7/10Novelty 8/10Timing: post-market today

Background

Novavax is a vaccine developer whose Q3 results were released on Nov 5, 2026.

Company-level read

Ticker impact

$NVAXBearishHigh confidence
Context

Novavax reported Q3 EPS of $-0.190 beating estimates by $0.03, but revenue of $68M missed the $77.2M consensus.

Expected impact

likely downside as investors price in weaker revenue

Evidence & confidence

Revenue fell short of expectations by ~12%, a material miss for a revenue‑sensitive biotech, while EPS beat was minimal.

Market effects

Sector

May weigh on other vaccine and biotech stocks as revenue expectations tighten.

Regional

Limited to US biotech sector; no broader regional effect.

Global

Minimal global impact beyond investors tracking biotech earnings.

Counterpoint

What could challenge this read

The EPS beat could signal operational efficiency, suggesting the stock may hold or rebound.

Key entities

  • Company
    Novavax

    Vaccine developer listed on NASDAQ.

Read at source← All news

StoryNovavax Raises 2026 Revenue Guidance After Sanofi Vaccine Milestone

Also covered by

4 outlets

Related articles

$NVAXMed

Novavax Q3 Earnings Call Highlights

Novavax reported Q3 revenue of $68M, down from $70M YoY, with a net loss of $31M, improved from a $202M loss last year. The company reduced expenses by 41% YoY and expects its cash runway to extend into 2029. Novavax plans to start clinical testing for its C. diff vaccine candidate in 2027 and is exploring oncology applications for its Matrix-M adjuvant. The company aims to reduce expenses to $150M-$200M by 2028.

finance.yahoo.com
$NVAXMed

Novavax (NVAX) Q3 2026 Earnings Call Transcript

Novavax (NVAX) reported Q3 2026 earnings, highlighting a $125 million milestone from Sanofi's phase III trial of a combination flu-COVID vaccine. The company expects additional milestones and revenue from partnerships. Novavax also plans to advance its C. diff vaccine candidate and expand into oncology. The company raised its full-year revenue outlook and improved expense guidance.

finance.yahoo.com
$NVAXHighAI 8/10

Novavax Beats On A Narrower Loss And Lifts Its Outlook On Sanofi's $125 Million Milestone, But Its Profitability Target Slides To 2029

Novavax reported a narrower-than-expected Q3 loss of $0.19 per share, beating estimates by $0.18, with revenue of $68.3M, exceeding expectations by $17.7M. The company raised its full-year revenue outlook to $400M, including a $125M milestone from Sanofi. However, profitability is now expected in 2029, pushed back from 2028, due to delayed milestones and reduced recurring revenue.

finviz.com